Trial Profile

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Regorafenib (Primary) ; Trametinib (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CheckMate9N9
Sponsors Bristol-Myers Squibb

Most Recent Events

11 Dec 2024 Status changed from active, no longer recruiting to completed.
31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
19 Aug 2024 Planned End Date changed from 11 Mar 2024 to 15 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com